As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.

The drug remains likely to get approval in Europe, but for now stuck in fourth-line treatment. The company’s pipeline lacks other near-term catalysts.

A new report from Informa's Meddevicetracker outlines the market drivers and competitive landscape for the carotid artery stents and embolic protection devices market.

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.